An Open-Label, Multicenter, Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Intravenous Doses of Inhibrx rhAAT-Fc (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD)

R
Ryan Boente

Primary Investigator

Overview

The purpose of the study is to assess safety and tolerability of a Phase I drug, INBRX-101 in patients with alpha-1 antitrypsin deficiency (AATD).

Description

Here at IU Health, we are recruiting for clinical trial to study the effects of a new drug on Alpha-1 Antitrypsin Deficiency (AATD).  All study procedures will take place at University Hospital at no cost to you.  You will be compensated for your time and effort.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Alpha-1 Antitrypsin Deficiency (AATD)
  • Age: Between 18 Years - 70 Years
  • Gender: All

Inclusion Criteria
AATD diagnosis, willing to undergo 2 bronchoscopies

Non-smoker

Willing to hold current AATD treatment until study ends (about 5 months).

Updated on 18 Apr 2023. Study ID: 1902734320

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center